

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Previously Presented) An anti-IFNAR2 antibody selected from the group consisting of antibody 1F3 produced by a hybridoma cell line with ATCC Accession No. HB 12426 antibody 3B7 produced by a hybridoma cell line with ATCC Accession No. HB 12427 and antibody 1D3 produced by the hybridoma cell line with ATCC Accession No. HB 12428.
2. (Cancelled)
3. (Currently Amended) A polypeptide comprising a portion of the antibody of claim 1 or 2, wherein said portion comprises an antigen binding fragment of said antibody.
4. (Cancelled)
5. (Previously Presented) The antibody of claim 1, wherein said antibody does not substantially block binding of a Type I interferon to IFNAR2.
6. (Original) The antibody of claim 5, wherein said Type I interferon is IFN $\alpha$ -2/1.
7. (Currently Amended) The antibody of claim 1, wherein said antibody blocks anti-viral activity of a first Type I interferon and does not block anti-viral activity of IFN $\beta$  a ~~second Type I interferon~~.
- 8 (Currently Amended) The antibody of claim ~~[[5]]~~ 7, wherein said antibody competes for binding to IFNAR2 with antibody 1D3 produced by a hybridoma cell line with ATCC Accession No. HB 12428.

9. (Withdrawn and Currently Amended) The antibody of claim 8 ~~2-or-3~~, wherein said antibody is a monoclonal antibody.

10. (Withdrawn and Currently Amended) The antibody of claim 8 ~~2-or-3~~, wherein said antibody is a humanized antibody.

11. (Withdrawn and Currently Amended) The antibody of claim 8 ~~2-or-3~~, wherein said antibody is a human antibody.

12-13. (Cancelled)

14. (Withdrawn and Currently Amended) A composition comprising the antibody of any of claims ~~4-3~~ 1, 3, or 9-11 and an excipient.

15. (Currently Amended) An anti-IFNAR2 antibody ~~IF3~~ 1F3 produced by a hybridoma cell line with ATCC Accession No. HB 12426.

16. (Cancelled)

17. (Previously Presented) An anti-IFNAR2 antibody 3B7 produced by a hybridoma cell line with Accession No. HB 12427.

18. (Cancelled)

19. (Currently Amended) An anti-IFNAR2 antibody ~~that competes for binding to IFNAR2 with antibody ID3~~ 1D3 produced by a hybridoma cell line with ATCC Accession No. HB 12428.

20. (Cancelled)

21. (Previously Presented) The antibody of claim 7, wherein the antibody blocks the activity of IFN- $\alpha$ 8, IFN- $\alpha$ 5, IFN- $\alpha$ 2, and IFN- $\alpha$ 1.

22. (Cancelled)

23. (Currently Amended) The antibody of claim 1, wherein the antibody blocks ISGF ISGF3 complex formation.

24. (New) An anti-IFNAR2 antibody that blocks the antiviral activity of a first type I interferon, and does not block antiviral activity of IFN $\beta$ , binds to IFNAR2 and does not bind to IFNAR2 comprising an alanine at one or more amino acids 133, 134, 135, 139, 153, 154 and 156 of IFNAR2.

25. (New) An anti-IFNAR2 antibody that blocks the antiviral activity of a first type I interferon, binds to IFNAR2, and does not bind to IFNAR2 comprising an alanine at one or more amino acids 49, 51, 52, 54, 68, 71 and 72 of IFNAR2.

26. (New) An anti-IFNAR2 antibody that blocks the antiviral activity of a first type I interferon, binds to IFNAR2, and does not bind to IFNAR2 comprising an alanine at one or more amino acids 74, 77 and 78 of IFNAR2.

27. (New) An antibody that binds to IFNAR2 and comprises the CDRs of antibody 1F3 (ATCC Accession No. HB 12426).

28. (New) An antibody that binds to IFNAR2 and comprises the CDRs of antibody 1D3 (ATCC Accession No. HB 12428).

29. (New) An antibody that binds to IFNAR2 and comprises the CDRs of antibody 3B7 (ATCC Accession No. HB 12427).